Axis-Shield introduces assay for osteoporosis marker
This article was originally published in Clinica
Axis-Shield has developed an assay for detecting a genetic marker linked to osteoporosis. The test is based on identification of the unfavourable 'ss' allele of the COLIA1 gene - elderly individuals with this form of the gene are more than 3.5 times as likely to suffer a fracture as those with the 'SS' form. The test is so far only available for research use while the company builds awareness in the clinical community and generates sufficient data for regulatory approval for clinical use.
You may also be interested in...
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.